Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 31 of the 34 sources its claims cite were checked for support.

Imaging the effect of ketamine on synaptic density (SV2A) in the living brain

Open access

Abstract

The discovery of ketamine as a rapid and robust antidepressant marks the beginning of a new era in the treatment of psychiatric disorders. Ketamine is thought to produce rapid and sustained antidepressant effects through restoration of lost synaptic connections. We investigated this hypothesis in humans for the first time using positron emission tomography (PET) and [11 C]UCB-J-a radioligand that binds to the synaptic vesicle protein 2A (SV2A) and provides an index of axon terminal density. Overall, we did not find evidence of a measurable effect on SV2A density 24 h after a single administration of ketamine in non-human primates, healthy controls (HCs), or individuals with major depressive disorder (MDD) and/or posttraumatic stress disorder (PTSD), despite a robust reduction in symptoms. A post-hoc, exploratory analysis suggests that patients with lower SV2A density at baseline may exhibit increased SV2A density 24 h after ketamine. This increase in SV2A was associated with a reduction in depression severity, as well as an increase in dissociative symptoms. These initial findings suggest that a restoration of synaptic connections in patients with lower SV2A at baseline may underlie ketamine's therapeutic effects, however, this needs replication in a larger sample. Further work is needed to build on these initial findings and further establish the nuanced pre- and post-synaptic mechanisms underpinning ketamine's therapeutic effects.

Overview

CoChat Summary

TL;DR

This first-in-human study used [11C]UCB-J PET to test whether ketamine increases synaptic density (SV2A) in healthy controls and individuals with MDD and/or PTSD. It found no measurable overall SV2A change 24 hours after a single ketamine dose despite robust symptom reduction, but a post-hoc analysis suggested increases in those with lower baseline SV2A.

Key findings

  • No significant change in SV2A density ([11C]UCB-J VT) 24 hours after ketamine in healthy controls (n=9; mean change 0.5%) or clinical participants (n=12; mean change 2.4%) across dlPFC, ACC, or hippocampus (all p>0.05); group-by-time effects were also non-significant.
  • Ketamine produced robust antidepressant effects in the clinical group: MADRS reductions of -80±19% immediately, -66±24% at 24 hours, and -58±28% at 1 week (all p<0.001), alongside significant dissociative symptoms.
  • In a post-hoc median split, the “SV2A deficit” clinical subgroup (n=6) had lower baseline SV2A density than age/sex-matched HCs (n=25) in dlPFC (p=0.005), ACC (p=0.001), and hippocampus (p<0.001); after ketamine, SV2A increased in dlPFC (8.7%, p=0.046, d=1.1), ACC (10.4%, p=0.035, d=1.2), and hippocampus (7.0%, p=0.054, d=1.0).
  • In the “SV2A deficit” group, greater SV2A increase correlated with greater depressive symptom reduction in ACC (r=-0.91, p=0.011) and dlPFC (r=-0.818, p=0.047), and with derealization in ACC (r=0.817, p=0.047); non-human primates (n=4) showed no significant SV2A changes after ketamine or HNK at 24 hours, 1 week, or 4–6 weeks.

Methods

  • Human participants: n=9 healthy controls and n=12 clinical participants (3 MDD, 5 MDD/PTSD, 4 PTSD) received intravenous racemic ketamine 0.5 mg/kg over 40 minutes and underwent [11C]UCB-J PET at baseline and 24 hours post-ketamine; primary ROIs were dlPFC, ACC, and hippocampus, with VT quantified using a 1-tissue compartment model and metabolite-corrected arterial input.
  • Non-human primate study: four female rhesus macaques received ketamine 0.75 mg/kg IM or hydroxynorketamine (HNK) 1.5 or 3 mg/kg IM, with [11C]UCB-J PET at baseline and 24 hours, 1 week, and 4–6 weeks post-drug.
  • Analyses used linear mixed-effects models for SV2A density and Pearson’s r for correlations with symptom change; clinical measures included MADRS, HAMD-17, BDI, PCL-5/PCL-S, and CADSS.

Limitations

  • The paper states: the sample is small; the baseline-SV2A stratification analysis is post-hoc and exploratory and needs replication; clinical participants had mild-to-moderate symptom severity; a single ketamine dose may be insufficient; PET cannot distinguish synaptic density from vesicle number or SV2A expression; PET may be less sensitive than animal techniques; effects were highly variable; and change in free fraction (fP) correlated with change in VT in the “SV2A deficit” group.
  • Evident from the text: the non-human primate sample was only n=4, and the post-hoc human subgroups contained only n=6 each, limiting statistical power and generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41380-022-01465-2

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

18 Valid · 3 Not valid · 3 Not checked · 43 Own results and interpretations

37 more claims · 5 with their cited sources checked

Create a free account to see all 67 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 14
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

11 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 67 references

Research works printed but not linked: 1

  1. Kaufman MB. Pharmaceutical approval update. Pharm Ther. 2019;44:42–4.

Cited by

  • Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms

    Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262

    “To date there has been a single pilot study directly addressing whether the antidepressant response to ketamine is associated with restoration of synapse density [132].”
    BackgroundSelf-citation
  • Synaptic plasticity and mental health: methods, challenges and opportunities

    Appelbaum, L. G., Shenasa, M. A., Stolz, L., & Daskalakis, Z. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01370-w · Cited by 240

    “Interestingly, despite significant symptom reduction, there was no associated change in SV2A density however, post-hoc analyses suggested that ketamine’s therapeutic effect may lie in restoring synapses in patients with lower baseline SV2A levels [38].”
    Background
  • Synaptic Vesicle Glycoprotein 2A: Features and Functions

    Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123

    “The authors also completed a post hoc study, showing that patients with lower SV2A density at baseline may exhibit an increased SV2A density 24 h after ketamine administration, coherent with the reduction in severity of depression (Holmes et al., 2022).”
    Background
  • Canalization and plasticity in psychopathology

    Carhart-Harris, R. L., Chandaria, S., Erritzøe, D., Gazzaley, A. H., Girn, M., Kettner, H., Mediano, P. A. M., Nutt, D., Rosas, F. E., Roseman, L., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109398 · Cited by 114

    “Figuratively speaking, for the ‘internalizer’, belief-updating has ‘fallen into a rut’ (Holtzheimer and Mayberg, 2011); this person’s thinking and/or behavior has become entrenched in overly precise beliefs; they ‘go there’, likely because, given their experiences and circumstances (Maté, 2010),…”
    Background
  • Ketamine in neuropsychiatric disorders: an update

    Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108

    “…connectivity in participants, a recent study found that lower SV2A density at baseline in healthy volunteers and participants with MDD and/or PTSD predicted increases in SV2A density after ketamine administration; these increases, in turn, were associated with fewer depressive symptoms [208].”
    Result

See all 78

Metadata

Authors
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., Duman, R. S., Sanacora, G., Krystal, J. H., Carson, R. E., & Esterlis, I.
Affiliations
Yale University (US)
Corresponding author
  • Holmes, Sophie E.
  • Esterlis, Irina
Venue
Molecular Psychiatry
Published
2022-02-15
Volume
27
Issue
4
Pages
2273-2281
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4213048184
Cited by
78
References
67
Citations by year
2026: 16 · 2025: 16 · 2024: 23 · 2023: 15 · 2022: 8
FWCI
9.28
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR001863)
  • Brain and Behavior Research Foundation (NA)
  • Nancy Taylor Foundation for Chronic Diseases (NA)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
ketamine, synaptic density, SV2A, [11C]UCB-J, major depressive disorder, post-traumatic stress disorder, rapid-acting antidepressants, dissociative symptoms, depression severity
MeSH terms
Animals, Antidepressive Agents, Brain, Major Depressive Disorder, Humans, Ketamine, Macaca mulatta, Membrane Glycoproteins, Nerve Tissue Proteins, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. https://app.cochat.ai/papers/10.1038/s41380-022-01465-2
The paper
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., Duman, R. S., Sanacora, G., Krystal, J. H., Carson, R. E., & Esterlis, I. (2022). Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01465-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.